Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...
Source: prnewswire.com